Moderna · 4 months ago
2026 Intern, Biostatistics and Programming
Cambridge, Massachusetts
Internship
Onsite
Intern
$20/hr - $60/hrModerna is a leading company in mRNA technology, and they are seeking an intern to learn about the biotech industry. The intern will collaborate with scientists and statisticians to address data-related challenges in clinical studies and assist in developing tools and pipelines for data-driven solutions.
BiotechnologyGeneticsHealth CareMedicalPharmaceuticalTherapeutics
No H1B
U.S. Citizen Only
Responsibilities
Collaborate with scientists and statistical programmers to solve challenge data related problems in clinical studies and harmonize various data using clinical data standard
Build tools and pipelines for both scientists and statisticians to drive business solutions in a data driven way
Champion in bringing state-of-art statistical thinking and methods to help drive applications of suit-for-purpose statistical methods and visualizations that enhance the probability of successes for clinical development programs
Qualification
Required
PhD student or Master Student in statistics, biostatistics, computational biology, statistical genetics, data science or related disciplines
Excellent statistical knowledge and quantitative skill with the ability of applying the knowledge to solve scientific and clinical problems
Experience in R, AWS/GCP, and at least one programming language (e.g. Python or Perl) is essential
Experience with handling high dimensional data and create visualization apps
Outstanding communication skills (verbal and written)
Candidates must already hold work authorization in US and be able to maintain that status without the need for future sponsorship
Benefits
Free premium access to meditation and mindfulness classes
Subsidized commuter benefits
Generous paid time off, including vacation, sick time, holidays, volunteer days, and a discretionary year-end shutdown
Location-specific perks and extras
Company
Moderna
Moderna Therapeutics is a biotechnology company that specializes in vaccines and drug development.
Founded in 2010
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$4.56BKey Investors
Coalition for Epidemic Preparedness InnovationsAres ManagementU.S. Department of Health & Human Services
2025-12-18Grant· $54.3M
2025-11-20Post Ipo Debt· $600M
2024-07-02Grant· $176M
Leadership Team
Stephane Bancel
Founding CEO
Kenneth Chien
Co-Founder
Recent News
2026-01-22
Latest News From Euronews | Euronews RSS
2026-01-22
Company data provided by crunchbase